1. Generics Bulletin
  2. >>Products

Amgen Has US Rituximab Nod - But No RA Indication

Riabni Biosimilar Rival To Rituxan Seeks To Compete With Price Discount

 
• By Dave Wallace

Amgen has received FDA approval and revealed launch plans for its Riabni rituximab rival to Rituxan, setting a price discount in line with Pfizer’s Ruxience version. However, the biosimilar has not been approved for the rheumatoid arthritis indication that is enjoyed by Teva and Celltrion’s higher-priced Truxima version.

Cut Price Dollar Scissors
Amgen’s price discount matches that of Pfizer • Source: Shutterstock

Amgen has received US Food and Drug Administration approval for its Riabni (rituximab-arrx) biosimilar version of Rituxan, which the biotech giant intends to launch in the US in January 2021.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin